800-Patient study aims to unlock secrets of autoimmune liver disease

NCT ID NCT07594990

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune mechanisms behind these diseases, which could eventually lead to more effective treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why some patients respond to treatment and others do not, pointing toward more personalized therapies for autoimmune liver diseases.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new drug or cure, and results may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AP-HP Beaujon

    Clichy, France

  • AP-HP Paul Brousse

    Villejuif, France

  • AP-HP Saint-Antoine

    Paris, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHU Nantes

    Nantes, France

  • CHU Poitiers

    Poitiers, France

  • CHU d'Angers

    Angers, France

  • CHU de Brest

    Brest, France

  • CHU de Lille

    Lille, France

  • CHU de Rennes

    Rennes, France

  • CHU de Toulouse

    Toulouse, France

  • CHU de Tours

    Tours, France

  • Hospices Civils de Lyon

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.